Antiangiogenic and antitumor activity of LP-261, a novel oral tubulin binding agent, alone and in combination with bevacizumab. - Gardner ER; Kelly M; Springman E; Lee KJ; Li H; Moore W; Figg WD (Investigational new drugs, 2012)